Biotechnologies
ACCELERATING INNOVATIVE

We Acquire, Develop and Finance Undervalued Biomedical Assets

Slider

Our vision is to create a pipeline of innovative biomedical assets in various stages of development in multiple therapeutic areas. Our strategy will minimize risk, share success and accelerate our technologies from incubation to monetization.

Q BioMed Announces Development Partnership With Sphaera Pharma

Sphaera to Provide Proprietary Patentable Analogue of QBM-001 for IND filingNEW YORK, September 19, 2017 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new and...

Q BioMed Inc. Closes $3,050,390 Equity Financing

Funding Provides Capital to Meet Near Term Milestones and CatalystsNEW YORK, August 2, 2017 /PRNewswire/ --Q BioMed Inc. (OTCQB: QBIO) is pleased to announce the closing of a $3,050,390 equity financing. The financing with a small group of accredited investors...

Q BioMed Inc. to be Featured on CEO Clips Airing on Bloomberg Television

NEW YORK, July 10, 2017 /PRNewswire/ --Q BioMed Inc. (QBIO) will be featured on CEO Clips airing on Bloomberg Television July 10 through 14th. CEO Clips, profiles some of the most innovative publicly traded companies in North America and will feature a :15 to :30 sec...

OUR GROWING PIPELINE MITIGATES RISK

Progress
0%

Topical eyedrops for glaucoma

PRECLINICAL

Image is not available
Progress
0%

PRECLINICAL

Chemotherapeutic for liver cancer

Image is not available
Progress
0%

Rare pediatric non-verbal Autism Spectrum Disorder

PRE IND 2/3

Image is not available
Progress
0%

COMMERCIALIZATION

Radio-pharmaceutical for metastatic cancer bone pain

Image is not available
Arrow
Arrow
Slider

OUR PORTFOLIO

METASTATIC CANCER BONE PAIN
CHEMOTHERAPUTIC FOR LIVER CANCER
RARE PEDIATRIC NON-VERBAL DISORDER
TOPICAL EYEDROPS FOR GLAUCOMA & IOP

THE RIGHT
FIRM

Focuses exclusively in the biotechnology and healthcare sectors, targeting a broad spectrum of biomedical products and healthcare solutions. Q’s expertise is in business & product development and the capital formation required for phased advancement of products.

THE RIGHT
SOLUTION

Our team assists companies by utilizing our strategic partners and network of experts to provide public market access for private company assets.  80% of biomedical start ups lack capital and resources to transition from incubation to development and beyond.

THE RIGHT
STRATEGY

Q expects to maximize risk-adjusted returns by focusing on value-driven assets from early stage to near-revenue businesses where the technical, regulatory, and commercial risks have been mitigated or where major valuation inflections are imminent.

SIGN UP FOR UPDATES FROM Q BIOMED

Copyright © 2017 Q BioMed, Inc. All Rights Reserved

CONTACT

501 Madison Ave, 14th Floor
New York, NY 10022 USA
P: +1 888 357 2435
E: info@qbiomed.com